Actuate Therapeutics, Inc ACTU IPO will take place July, 24 on the NASDAQ exchange under the ticker ACTU.
The company is offering shares at an expected price between $8.00 and $10.00 per share with an insider lock-up period of 180 days ending on January 20, 2025.
See also: Benzinga IPO Calendar
About Actuate Therapeutics, Inc
Actuate Therapeutics, Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
